Nanthealth LLC (NYSE:NH)’s share price reached a new 52-week low on Monday . The company traded as low as $10.58 and last traded at $10.75, with a volume of 50,396 shares. The stock had previously closed at $11.27.

A number of equities analysts recently weighed in on the stock. Cowen and Company assumed coverage on shares of Nanthealth in a research report on Monday, June 27th. They set an “outperform” rating and a $19.00 price objective for the company. FBR & Co initiated coverage on shares of Nanthealth in a report on Monday, June 27th. They set an “outperform” rating and a $18.00 target price on the stock. First Analysis initiated coverage on shares of Nanthealth in a report on Monday, June 27th. They set an “overweight” rating and a $18.00 target price on the stock. Jefferies Group initiated coverage on shares of Nanthealth in a report on Monday, June 27th. They set a “buy” rating on the stock. Finally, Canaccord Genuity initiated coverage on shares of Nanthealth in a report on Monday, June 27th. They set a “buy” rating and a $17.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $18.00.

The stock has a 50 day moving average price of $13.35 and a 200-day moving average price of $13.35. The firm’s market cap is $5.93 billion.

In other Nanthealth news, major shareholder Healthcare Solution Allscripts acquired 714,286 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The shares were purchased at an average price of $14.00 per share, with a total value of $10,000,004.00. Following the completion of the transaction, the insider now owns 15,000,000 shares in the company, valued at $210,000,000. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Patrick Soon-Shiong acquired 357,143 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.